drugset / Trial / NCT00255125

Role of Soy Supplementation in Prostate Cancer Development

NCT00255125 ↗

Phase 3 Completed 86 enrolled VA Office of Research and Development
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue. Patient will be randomized it either receive placebo or a commercial soy supplement for 2-4 weeks prior to the planned surgery for treatment of their prostate cancer. Patient's blood and prostate tissue will be evaluated to determine the effects of the soy supplement on the prostate tissue.

Timeline

Start
2005-09
Primary completion
2009-04
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Soy Supplement Unknown 80 mg Oral

Indications